Dupilumab Dosing for Adult COPD with Type 2 Inflammation
For adult COPD patients with eosinophils ≥300 cells/µL who remain symptomatic despite optimized triple inhaler therapy, administer dupilumab 300 mg subcutaneously every 2 weeks (Q2W) for at least 52 weeks. 1
Dosing Regimen
The FDA-approved dosing for COPD is straightforward:
- Initial dose: 300 mg subcutaneously
- Maintenance: 300 mg subcutaneously every 2 weeks (Q2W)
- Duration: Minimum 52 weeks to achieve sustained benefit 1
This dosing differs from other indications where loading doses are used. For COPD specifically, no loading dose is required—you start directly with 300 mg Q2W 1.
Administration Considerations
First injections should be administered in-hospital for training purposes and to monitor for the minimal risk of anaphylaxis 2. After the first 2 injections, patients can self-administer at home. The injection sites include abdomen, thigh, or upper arm using either auto-injector or pre-filled syringe 2.
Evidence Supporting This Dose
The 300 mg Q2W regimen demonstrated robust efficacy in the pivotal BOREAS trial 3:
- Exacerbation reduction: 30% reduction in annualized moderate/severe exacerbations (rate ratio 0.70,95% CI 0.58-0.86, P<0.001)
- Lung function improvement: 83 mL increase in prebronchodilator FEV1 at week 12 versus placebo, sustained through week 52
- Quality of life: -3.4 point improvement in SGRQ score at week 52 versus placebo (P=0.002)
- Symptom reduction: -1.1 point improvement in E-RS-COPD score versus placebo (P=0.001)
The NOTUS trial confirmed these findings with similar dosing, showing a 34% reduction in exacerbations (rate ratio 0.66,95% CI 0.54-0.82, P<0.001) 4.
Patient Selection Criteria
This dose is specifically indicated for patients meeting ALL of the following:
- Blood eosinophils ≥300 cells/µL at screening 3, 4
- Already on optimized triple therapy (LAMA/LABA/ICS)
- Persistent moderate-to-severe exacerbations despite triple therapy
- Type 2 inflammatory phenotype (eosinophilic COPD) 2
Important caveat: Higher baseline eosinophil counts and elevated FeNO predict greater treatment response, with those having higher eosinophils showing more pronounced exacerbation reduction (p=0.0056) 5. However, the approved threshold remains ≥300 cells/µL.
Timeline for Response
Onset of effect occurs within weeks to months 2. In clinical trials, significant improvements in prebronchodilator FEV1 were evident by week 12 and sustained through week 52 3. Exacerbation reduction benefits accumulate over the full 52-week treatment period.
Dosing Consistency Across Patient Subgroups
The 300 mg Q2W dose maintains efficacy regardless of:
No dose adjustments are needed based on these clinical characteristics 1.
Guideline Context
The 2025 EUFOREA guideline specifically identifies dupilumab as the biologic of choice for eosinophilic COPD 2. The 2023 Canadian Thoracic Society guidelines recommend adding therapies like macrolides, roflumilast, or N-acetylcysteine for patients who continue to exacerbate on triple therapy 8, but these guidelines predate dupilumab's COPD approval. Dupilumab now represents a disease-modifying option that directly targets the underlying type 2 inflammation rather than simply adding symptomatic therapies.
Safety Monitoring
The safety profile at 300 mg Q2W was comparable to placebo in COPD trials 3. Anti-drug antibodies developed in 8% of COPD patients, with neutralizing antibodies in 36% of those who developed ADAs, but this did not significantly impact clinical efficacy 1.